MedTrace Logo

HPP737 Substance Balance Study in Human

NCT06584058 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2024-09-04

No results posted yet for this study

Summary

Main research purpose

1. Quantitative analysis of the total amount of radioactivity in excreta (urine and feces) of male healthy subjects after oral administration of \[14C\]HPP737, to obtain the cumulative excretion rate and main excretion routes of human radioactivity;
2. To identify the main metabolites in the offspring of \[14C\]HPP737 in healthy male subjects, and to determine the main biotransformation pathway and main metabolite structure;
3. To investigate the distribution of total radioactivity in whole blood and plasma and the pharmacokinetics of total plasma radioactivity in healthy male subjects after a single oral administration of \[14C\]HPP737.

Participants will:

1. Take Investigational product once
2. Stay in the clinic about 7 days for checkups and tests
3. Report their symptoms

Conditions

Interventions

DRUG

HPP737

\[14C\]HPP737 oral preparation, 20mg（150μCi）, once

Sponsors & Collaborators

  • Newsoara Biopharma Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jie Pan, Master · Second Affiliated Hospital of Soochow University

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-08-30
Primary Completion
2025-07-30
Completion
2025-08-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06584058 on ClinicalTrials.gov